NetworkNewsBreaks – SOHM Inc.’s (SHMN) ABBIE Technology Poised to Make a Difference in the Lives of Millions
SOHM (OTC: SHMN), a global generic drug innovator, recently completed the acquisition of a disruptive stem cell technology ABBIE (A Binding Based Integrating Enzyme) and patents from CGA Intellectual Holdings Inc. “[The acquisition] will allow the company to create regenerative medicine and cosmeceutical products for commercialization during the next year. SOHM’s acquisition of ABBIE grants it the ability to edit genes of a large number of cell types at different stages in their life cycles, overcoming the limitations of current cell editing and cell engineering technologies, according to the company… SOHM intends to use ABBIE to edit the genes of stem cells that are recognized as the body’s foundational building blocks with the ability to change themselves into various function-specific genes. The edited genes would then be inserted into patients’ bodies using non-viral vectors to treat damaged organs in conditions such as ischemic heart disease or heart failure… SOHM expects to be able generating revenues immediately through licensing and gene-editing kits that are expected to be available in the third or fourth quarter of next year,” a recent article explains. “ABBIE will soon become a reality and make a difference in the lives of millions of people who suffer from heart disease,” SOHM COO David Aguilar, PhD, is quoted as saying.